Evidence map›Paper›PMID 33450392›Full record

ArticleNeurobiology of disease2021

Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease.

Megan M Senchuk, Jeremy M Van Raamsdonk, Darren J Moore

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Unraveling Molecular Targets for Neurodegenerative Diseases ThroughInternational journal of molecular sciences · 2025
    Review
  3. Article
  4. Regulation of TIR-1/SARM-1 by miR-71 Protects Dopaminergic Neurons in aInternational journal of molecular sciences · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Megan M SenchukDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, USA.
Jeremy M Van RaamsdonkDepartment of Neurology and Neurosurgery, McGill University, Montreal, Quebec H4A 3J1, Canada; Metabolic Disorders and Complications Program, Brain Repair and Integrative Neuroscience Program, Research Institute of the McGill University Health Centre, Montreal, Quebec H4A 3J1, Canada; Department of Genetics, Harvard Medical School, Cambridge, MA 02115, USA. Electronic address: jeremy.vanraamsdonk@mcgill.ca.
Darren J MooreDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, USA. Electronic address: darren.moore@vai.org.
Van Andel Institute · USMcGill University Health Centre · CA

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
Developing novel treatments for Parkinson's disease by targeting molecular pathways that have been shown to modulate agingR21AG058241 · NIA · VAN ANDEL RESEARCH INSTITUTE · PI MOORE, DARREN JOHN · 2018 to 2019
$523k
NIA NIH HHS R21 AG058241NIH HHS P40 OD010440
6 · The paper itself

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent cause of late-onset, familial Parkinson's disease (PD), and LRRK2 variants are associated with increased risk for sporadic PD. While advanced age represents the strongest risk factor for disease development, it remains unclear how different age-related pathways interact to regulate LRRK2-driven late-onset PD. In this study, we employ a C. elegans model expressing PD-linked G2019S LRRK2 to examine the interplay between age-related pathways and LRRK2-induced dopaminergic neurodegeneration. We find that multiple genetic pathways that regulate lifespan extension can provide robust neuroprotection against mutant LRRK2. However, the level of neuroprotection does not strictly correlate with the magnitude of lifespan extension, suggesting that lifespan can be experimentally dissociated from neuroprotection. Using tissue-specific RNAi, we demonstrate that lifespan-regulating pathways, including insulin/insulin-like growth factor-1 (IGF-1) signaling, target of rapamycin (TOR), and mitochondrial respiration, can be directly manipulated in neurons to mediate neuroprotection. We extend this finding for AGE-1/PI3K, where pan-neuronal versus dopaminergic neuronal restoration of AGE-1 reveals both cell-autonomous and non-cell-autonomous neuroprotective mechanisms downstream of insulin signaling. Our data demonstrate the importance of distinct lifespan-regulating pathways in the pathogenesis of LRRK2-linked PD, and suggest that extended longevity is broadly neuroprotective via the actions of these pathways at least in part within neurons. This study further highlights the complex interplay that occurs between cells and tissues during organismal aging and disease manifestation.

Indexed as

AgingAnimalsCaenorhabditis elegansDisease Models, AnimalLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LongevityParkinsonian DisordersLeucine-Rich Repeat Serine-Threonine Protein Kinase-2InsulinKinaseLifespanLRRK2NematodeNeurodegenerationNeuroprotectionParkinson's diseaseSignaling

Identifiers

PMID33450392
PMCPMC7925424
OpenAlexW3120508707

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.